<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04903340</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/60</org_study_id>
    <nct_id>NCT04903340</nct_id>
  </id_info>
  <brief_title>Assessment of the Impact of Acquisition Time, Respiratory Gating and New Qclear Reconstruction Modalities on the Quantification of Dosimetry in Selective Internal Radiotherapy</brief_title>
  <acronym>PYR</acronym>
  <official_title>Assessment of the Impact of Acquisition Time, Respiratory Gating and New Qclear Reconstruction Modalities on the Quantification of Dosimetry in Selective Internal Radiotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Post-processing of Positron Emission Tomography (PET) acquired images, performed following&#xD;
      radioembolization treatment with microspheres at 90Y in hepatocellular carcinoma patients, is&#xD;
      subject to changes commercialized by General Electric : respiratory motion correction,&#xD;
      specific reconstruction algorithms. We propose to test the possible combinations of these&#xD;
      reconstruction parameters to determine which ones to apply for an optimal quality exam with&#xD;
      the shortest scan time possible&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 12, 2021</start_date>
  <completion_date type="Anticipated">December 12, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Average dose value (Gy) of tumor liver and healthy liver obtained according to reconstruction configuration.</measure>
    <time_frame>Day 0 (PET/CT Exam)</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>PET/CT Exam</intervention_name>
    <description>PET/CT image processing application of reconstruction parameters: scan time, respiratory gating, Q-clear</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with hepatocellular carcinoma&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient with hepatocellular carcinoma&#xD;
&#xD;
          -  with radioembolization treatment decided&#xD;
&#xD;
          -  over the age of 18&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  radiembolization not possible&#xD;
&#xD;
          -  acquisition of PET/CT imaging at 90Y not possible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>LAMARE Frederic</last_name>
    <phone>05 57 82 00 00</phone>
    <email>frederic.lamare@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lamare Frederic</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2021</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

